Literature DB >> 3673580

Immunological relation between serum antibodies against pneumolysin and against streptolysin O.

K Kanclerski1, M Granström, R Möllby.   

Abstract

The immunological relation between serum antibodies to pneumolysin and to streptolysin O was studied in patients with pneumococcal pneumonia (n = 40), patients with infections due to beta-haemolytic streptococci (n = 35), healthy human controls (n = 60) and in rabbits immunized with pneumolysin. There was no correlation between anti-pneumolysin and anti-streptolysin O titers (r = -0.279). The distribution of anti-pneumolysin titers in patients with high anti-streptolysin O titers did not differ from healthy controls. However, there was a tendency to increased or rising anti-streptolysin O titers in patients with pneumococcal infection. Antibodies obtained during pneumococcal infection might thus give false-positive reactions in the streptolysin O neutralization test. Serum antibodies to streptolysin O do not cross-react with pneumolysin in an ELISA. The pneumolysin ELISA for detection of pneumococcal disease will therefore not be disturbed by false-positive reactions due to antibodies directed against beta-haemolytic streptococci.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3673580     DOI: 10.1111/j.1699-0463.1987.tb03119.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Immunol Scand B        ISSN: 0108-0180


  3 in total

1.  Validation of immune-complex enzyme immunoassays for diagnosis of pneumococcal pneumonia among adults in Kenya.

Authors:  J A Scott; A J Hall; M Leinonen
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

2.  Sera from patients with high titers of antibody to streptolysin O react with listeriolysin.

Authors:  S Chatzipanagiotou; H Hof
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

3.  Mapping of immunoreactive sites of pneumococcal pneumolysin by use of synthetic peptides.

Authors:  P Salo; A Närvänen; M Leinonen
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.